Such as the september 24th PR
The electronic publication of the peer-reviewed article is now available in the Journal of Surgical Research at http://www.journalofsurgicalresearch.com/article/S0022-4804(14)00803-8/abstract. The paper was authored by Geoffrey C. Gurtner, MD, FACS; Thomas J. Koob, PhD; William W. Li, PhD; Zeshaan N. Mann, MBBS, MS, MRCS; and Robert C. Rennert, BA. The hard copy publication is expected to follow in a future issue of the Journal of Surgical Research.
Candy, my post was not directed at you, only at those capable of understanding the science explained in the article. "The thoughta and opinions expressed in this supplement are those of the authors and not necessarily MiMedx." You forgot that part, conveniently.
Bioengineered Skin and Tissue
References updated. Policy Statement updated to include Epifix® coverage if meets medical necessity criteria. "When Covered" section updated to include Epifix as considered medically necessary for the treatment of chronic, non-infected full-thickness diabetic or neuropathic lower extremity ulcers. "When Not Covered" section updated to include additional products and to remove Epifix. Medical Director review 2/2015.
he doesn't need to sit down with them to accomplish what he is trying to do. he has no understanding of what the company does, their business model, etc., nor does he care.
What kind of analyst forecasts a company to go from $118 million revenue to $190 million in one year and rates the company "underperform"? Wait, don't answer that.
Yes, Shorty and the mob are back. His note titled "Does bullish outlook properly discount risks on the horizon"? Yes, the same risks he has been spouting off about forever that have never impacted the business! "the company continued to present a very bullish scenario for its business. MiMedx' FY15 outlook juztaposed with all the risks posed by reimbursement changes (he still doesn't get it), multitude of lawsuits, OIG subpoena (Guess he didn't have the dial in for the conf call) and competition provide for the makings of an interesting story in FY15. he talks about the reimbursement guarantee which is one of the two OIG issues and comments "While we don't understand the exact mechanic of this reimbursement guarantee..." Has anyone ever seen an analyst who in every single note talks about not understanding something??? Here's the best part. "On a macro level there appear to be questionable sales practices in the field in general. We cannot reconcile all the statements regarding superiority vs other grafts, correlation betwwen growth factors and wound healing and finally the healing rates within the contect of a 361 reg and homologous use is beyong our comprehensiion. (what isn't beyond your comprehension. Alegbra 1 probably is). We don't buy the argument that packaged reimbursement will not impact growth rates moving forward."
So, there is the shorty view. It won't matter if MDXG keeps beatings its numbers this year, he will continue to spout off about the reimbursement concern. He is concerned about growth yet, his model has MDXG doing $190 million this year, the TOP end of the company's guidance! if you don't buy it, why do you forecast a 61% increase in revenues this year??? LOL! How can anyone take him seriously. Could he actuially be candy/cez? Their intellect seems comparable.
Yes, he was advised by the mob and the chubby reporter when the stock was $5 to short it to $3. Sucks to be him.
candy, I mean cez, if you knew anything about the company, which you don't, you would have seen that the company bought back an inconsequential about of stock so that has not been a factor. Also, the general counsel was supposed to retire mid 2013 but was asked to stay on while they brought on her replacement to work with her for a while. That person is now assuming her role. And yes, I agree that Pete and his management team do deserve nice fat bonuses and I hope they take good care of themselves. Unlike many management teams whose performance does not warrant obscene cash bonuses or restricted stock grants because their companies have not performed and neither has their stock in terms of rewarding shareholders, I have no problem rewarding a management team who has grown the company from nothing to $200 million in a few years and who have rewarded shareholders with a 1000% return in 4 years or less.
Yes cez, you are a jerk and a pathetic one at that. Come clean already and tell the board whether you are a
terminated MDXG employee that couldn't cut it, an employee at a competitor or a paid basher. The latter is the most likely. As far as being a racist, I am only a racist when it comes to your particular species. I have nothing but admiration for people of Suraj' nationality. But, I take nothing back in terms of my comments addressed towards him. In my opinion, he has been working with the mob and street sweeper because no analyst could be as dumb and clueless as he is if one has read his notes the last couple of years. In my opinion he is to analysts what the ambulance chasers are to the legal profession and deserves any verbal stone thrown his way.
Well, no. Can't sue for a short gone bad. Shorts will just have to buy an extra supply of KY jelly for their reck-tums.
seldom. I pointed that out last year. Candy/cez/chubbyreporter has been the perfect contraindicator. His record is flawless. Buy when he says "sell,sell,sell" and 100% of his predictions on outcomes whether they be issues, sales,etc have been wrong. it's almost uncanny how someone can be 100% wrong. You would thing given the laws of averages he might guess something right just once, you know the old line about even the blind squirrelfinding the nut. He hasn't found even a single shell.